UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 23, 2014
Emmaus Life Sciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
Delaware |
|
000-53072 |
|
41-2254389 |
|
(State or Other Jurisdiction |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
of Incorporation) |
|
|
|
|
20725 S. Western Avenue, Suite 136, Torrance, CA 90501
(Address, including zip code, off principal executive offices)
Registrant’s telephone number, including area code 310-214-0065
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure
On October 23, 2014, in connection with providing an update to its stockholders at its annual meeting, Emmaus Life Sciences, Inc. (the “Company”) intends to report that it is exploring public funding, having already submitted a draft registration statement to the Securities and Exchange Commission on a confidential basis as permitted by the Jobs Act. The Company also intends to describe future milestones to include pursuing additional funding through a public offering, license agreements, other funding opportunities or a combination of the foregoing. This Form 8-K filing does not constitute an offer of any securities for sale.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Emmaus Life Sciences, Inc. | |
|
|
| |
|
|
| |
|
Date: October 23, 2014 |
| |
|
|
| |
|
|
By: |
/s/ Peter Ludlum |
|
|
Name: |
Peter Ludlum |
|
|
Title: |
Chief Financial Officer |